Novartis Expands Access With Direct-To-Patient Cosentyx Model In U.S. Launching November 2025

Novartis announced today that it will launch a direct-to-patient (DTP) platform in the U.S. starting November 1, 2025. The program will initially focus on Cosentyx® (secukinumab), offering eligible cash-paying patients a 55% discount off its list price. Cosentyx is Novartis’ top-selling product in the U.S. and is approved to treat a range of immune-mediated inflammatory diseases, including psoriasis, psoriatic arthritis, hidradenitis suppurativa, and ankylosing spondylitis.

Through this DTP model, Novartis aims to align patient prices more closely with the average discounts negotiated by insurers and pharmacy benefit managers. The initiative will serve as proof-of-concept for direct distribution of speciality medicines, potentially working alongside insurance to improve affordability. In addition, Novartis is exploring a direct-to-business approach by partnering with large employers to expand access to Cosentyx and potentially other therapies.

“Breakthrough innovation is what drives us at Novartis, in scientific research, medicine development, and in the ways in which we deliver our innovation to patients. In the US, we have long recognized that we need new ways to reach patients more directly by removing barriers in the system,” said Victor Bultó, President, US for Novartis. “The launch of this new platform is a first step as we continue to work toward solutions to provide our net prices more directly to patients and make the healthcare system work better for Americans.” 

Cosentyx, a fully human biologic that inhibits interleukin-17A, has been studied for more than 17 years and supported by a decade of real-world data. Since its launch in 2015, the therapy has been prescribed to over 1.8 million patients globally and is now approved in more than 100 countries. Its long-term safety and efficacy data reinforce Novartis’ strategy to broaden access to innovative biologics while addressing rising concerns over affordability.